TO THE EDITOR Basal cell carcinomas (BCCs) are the most common cancers in the United States, with an annual national incidence of~2 million (Lomas et al., 2012) . Although the majority are localized to the skin and cured by surgery, in rare cases, they can progress to advanced and metastatic tumors that result in severe morbidity and death. BCCs are typically caused by activating mutations in the sonic hedgehog (HH) pathway, most commonly through loss of the receptor Patched1 (PTCH1) or activation of the G-protein-coupled receptor Smoothened (SMO; Epstein, 2008) . Here, we report the presence of Kinastrin (kinetochorelocalized astrin/SPAG5 binding protein (KNSTRN)) mutations in BCC. KNSTRN encodes a kinetochore-associated protein that is an essential component of the mitotic spindle and is required for faithful chromosomal segregation during mitosis (Fang et al., 2009) . It is expressed in a broad range of tissues, including skin, and its mutations have been detected in both squamous-cell carcinoma (SCC) and melanoma, leading to its recent classification as an oncogene (Lee et al., 2014) .
In order to elucidate the role of KNSTRN in BCC, we interrogated 18 advanced (inoperable and 43 cm in size) and 30 early stage (o2 cm in size) BCCs for mutations in KNSTRN (Stanford Human Subjects panel approval and subsequent written informed consent was obtained from patients for tumor sequencing (Protocol 18325)). Among the advanced BCCs, whole-exome sequencing revealed a mean of 1,428 somatic coding mutations per tumor, equivalent to a nonsynonymous singlenucleotide variant rate of 47.6 per Mb (range 5.5-125.6 per Mb), which is in the low range of previous reports (Jayaraman et al., 2014; Atwood et al., 2015) . In addition, all tumors had a mutational profile characteristic of exposure to UV radiation, with C → T and A → T transitions present in 68% of alterations (SD 21%; Figure 1a ). In all, 72% of samples harbored mutations in PTCH1 or SMO, consistent with the known pathogenesis of BCC (Figure 1a and b; Jayaraman et al., 2014; Atwood et al., 2015) .
Interestingly, 4 advanced BCCs (21%) contained somatic mutations in KNSTRN (Figure 1a and c) . Three harbored the KNSTRN p.S24F mutation, which has previously been detected in both SCC and melanoma (Lee et al., 2014) . The affected region of KNSTRN corresponds to a UV-signature hotspot and involves a C→ T transition characteristic of UV-induced mutagenesis. KNSTRN p. S24F is predicted to be deleterious by SIFT (Ng and Henikoff, 2001) and Polyphen (Sunyaev et al., 2000) , and disrupts chromatid cohesion, increases aneuploidy, and promotes Ras-driven tumorigenesis in cell-based assays of keratinocytes and in vivo mouse models (Lee et al., 2014) . The fourth advanced BCC contained two KNSTRN mutations, p.L9P and p.V12G, both of which were predicted to be non-damaging by SIFT and Polyphen; however, identical mutations have been detected in liver, lung, and gastric cancer, supporting a role in tumorigenesis. KNSTRN p.S24F, p.L9P, and p.V12G have all been reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) and are absent from dbSNP137 and ESP6500 (Figure 1c Mutant KNSTRN has been functionally shown to disrupt sister chromatid cohesion and chromosome segregation in keratinocytes; in KNSTRN-mutated SCCs, this results in enhanced tumor aneuploidy and increased genomic copynumber aberrations (Lee et al., 2014) . To evaluate the functional relevance of mutated KNSTRN in BCC, we expressed wild-type-or S24F-mutated KNSTRN in a murine BCC cell line ( Figure 2a) and assessed chromosome segregation during mitosis. Interestingly, we found that mutant KNSTRN expression disrupted sister chromatid cohesion, as demonstrated by a higher percentage of unpaired sister chromatids in these cells (Figure 2b and c). In conjunction with similar functional studies in primary human keratinocytes and SCCs (Lee et al., 2014) , these data support a role for KNSTRN in maintaining chromosomal stability. To investigate large-scale genomic instability and tumor aneuploidy in our advanced BCCs, we employed a Bayesian-based algorithm, BIC-seq, to detect the copynumber variations (CNVs) in our samples (Xi et al., 2011) . PTCH1 deletions were detected in 12% of tumors, consistent with previous reports (Jayaraman et al., 2014) . There was a wide range in the number of CNVs among both KNSTRNmutated and KNSTRN-wild-type samples (Figure 1e ), suggesting that advanced BCCs have a large range of genetic instability. On average, 1.9% (SD 2.0%) of the exome was affected by CNVs in KNSTRN-mutated tumors versus 1.4% (SD 3.0%) in KNSTRN-wild-type tumors (P = 0.74). Although this was not statistically significant, our ability to detect differences may have been limited by a small sample size. 
Mutations in the Gene KNSTRN in BCCs
In SCC, KNSTRN p.S24F is present in 19% of tumor precursors, suggesting that it arises early in disease progression (Lee et al., 2014) . To determine whether KNSTRN mutagenesis is an early event in BCC development as well, we screened 30 early stage BCCs for KNSTRN mutations. We identified a nonsynonymous KNSTRN mutation in only 1/30 (3%) early stage BCCs, suggesting that, unlike in SCC, mutant KNSTRN in BCC appears to be acquired later in disease and is possibly a marker of aggressive behavior (Figure 1c and f) . The mutation, pH284D, is absent from dbSNP137 and ESP6500 and is predicted to be deleterious by SIFT; however, it has not previously been reported in the COSMIC database and is not predicted to be damaging by Polyphen.
These findings are the first to implicate KNSTRN in BCC tumorigenesis. Alongside recent data offering a role for KNSTRN in SCC and melanoma, our work supports the classification of KNSTRN as an oncogene and an important contributor to the pathogenesis of malignancies related to UVexposure. In both SCC and BCC, mutant KNSTRN disrupts sister chromatid cohesion and promotes genomic instability in functional assays. However, unlike in SCC, KNSTRN mutations in BCC appear to occur late in disease progression and are preferentially found in advanced tumors. Further exploration of the role of KNSTRN in skin cancer and genomic stability is warranted. 
